Novotech, HSITPL sign agreement for biotech support in HK-Shenzhen park

Novotech is one of 14 international firms selected to partner with HSITPL.

Novotech signed a Memorandum of Understanding (MOU) with Hong Kong-Shenzhen Innovation and Technology Park Limited (HSITPL) to boost clinical development support for biotech and community companies within the new 87-hectare Hong Kong-Shenzhen Innovation and Technology Park.

Novotech was one of the 14 international companies selected from approximately 60 partners across nine economies to collaborate with HSITPL.

Under the partnership, Novotech will offer consultation services to the Park's community firms and utilize its expertise to accelerate clinical trial development for biotech companies in the Park.

HSITPL will aid Novotech in assisting community companies within the Park in their development and growth whilst also providing essential support and resources to Novotech for establishing R&D centres within the Park.